Despite recent advances in antiviral drug development, hepatitis C virus (HCV) remains a major cause of chronic liver disease and cancer, access to therapy is limited, drug resistance evolves rapidly, and there is no effective vaccine. Thus, there is an unmet need to improve therapy and to create a vaccine. As most antiviral vaccines elicit humoral responses against virus particles, further research is needed to understand the structure and assembly of HCV particles, which are protected from antibody neutralization through an as-yet-uncharacterized interaction with serum lipoproteins. HCV is also a valuable model system for understanding the Flaviviridae - a large family of clinically important viral pathogens - as well as positive-strand RNA viruses more generally. A key unanswered question is how do positive-strand RNA virus-encoded helicases contribute to virus assembly? This proposal builds upon our success in the previous funding period to examine HCV particle assembly, both as a unique paradigm of virus structure and as a model system for understanding helicase function. By leveraging our prior success and adapting new approaches, we will achieve the following three Aims: 1) establish the role of the HCV helicase domain in virus assembly; (2) define functional interactions within the virus assembly complex; and (3) determine the role of Apolipoprotein E in virus structure. Successful completion of this Project will lay the groundwork for understanding, at a deep mechanistic level, the role of viral helicases during the assembly of enveloped, positive-strand RNA viruses, provide insights into the coordination of nucleocapsid assembly, and - for the first time - rigorously test the prevailing model of HCV particle structure.
We are elucidating the structure of infectious hepatitis C virus (HCV) particles and studying their mechanism of assembly. HCV and related viruses represent major threats to public health, and an understanding of their molecular behavior will facilitate th design of new or improved therapies and vaccines. HCV is now an important model system for guiding research on all positive-strand RNA viruses, thereby providing insights into new and emerging infections.
|Denolly, Solène; Mialon, Chloé; Bourlet, Thomas et al. (2017) The amino-terminus of the hepatitis C virus (HCV) p7 viroporin and its cleavage from glycoprotein E2-p7 precursor determine specific infectivity and secretion levels of HCV particle types. PLoS Pathog 13:e1006774|
|Fink, Susan L; Jayewickreme, Teshika R; Molony, Ryan D et al. (2017) IRE1? promotes viral infection by conferring resistance to apoptosis. Sci Signal 10:|
|Barouch-Bentov, Rina; Neveu, Gregory; Xiao, Fei et al. (2016) Hepatitis C Virus Proteins Interact with the Endosomal Sorting Complex Required for Transport (ESCRT) Machinery via Ubiquitination To Facilitate Viral Envelopment. MBio 7:|
|Lindenbach, Brett D; Rice, Charles M (2013) The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 11:688-700|
|Lindenbach, Brett D (2013) Virion assembly and release. Curr Top Microbiol Immunol 369:199-218|
|Stapleford, Kenneth A; Lindenbach, Brett D (2011) Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J Virol 85:1706-17|
|Phan, Tung; Kohlway, Andrew; Dimberu, Peniel et al. (2011) The acidic domain of hepatitis C virus NS4A contributes to RNA replication and virus particle assembly. J Virol 85:1193-204|
|Counihan, Natalie A; Rawlinson, Stephen M; Lindenbach, Brett D (2011) Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS Pathog 7:e1002302|
|Lindenbach, Brett D (2010) New cell culture models of hepatitis C virus entry, replication, and virus production. Gastroenterology 139:1090-3|